Scribe Therapeutics, which went public in late July at $15 per share, has seen its stock price rise over 44% since the IPO, outperforming the broader market. Analysts from Wells Fargo, Leerink Partners, and Guggenheim have initiated coverage with positive ratings and ambitious price targets.
Wells Fargo set a target of $60, indicating a potential 183% upside, while Leerink Partners and Guggenheim set targets of $37 and $50, respectively, suggesting increases of 75% and 136%. The analysts highlight Scribe's unique approach to gene editing, particularly its epigenetic silencing technology, which could provide long-lasting therapeutic effects without permanent genetic modification.
This positions Scribe as a leader in the gene-based therapeutics sector, especially as it prepares for key clinical data expected in the first half of 2027. The company's proprietary systems, X-Editor and Epigenetic Long-Term X-Repressor, enhance its gene-editing capabilities, further solidifying its competitive edge in the market